Arena bounces back. Stock soars on ozanimod rival's PhII success
Its diet pill was a commercial flop that almost sent Arena to the grave. Now — with its second pipeline drug reporting positive mid-stage data …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
